Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RDY’s FA Score shows that 1 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RDY’s TA Score shows that 4 TA indicator(s) are bullish.
RDY (@Pharmaceuticals: Other) experienced а -3.35% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +35.96%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was +19255.10%.
RDY is expected to report earnings on Jul 25, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
RDY | ||
---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 24 | |
SMR RATING 1..100 | 45 | |
PRICE GROWTH RATING 1..100 | 54 | |
P/E GROWTH RATING 1..100 | 78 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDY | ROAM | |
---|---|---|
RSI ODDS (%) | 2 days ago62% | 2 days ago76% |
Stochastic ODDS (%) | 2 days ago61% | 2 days ago83% |
Momentum ODDS (%) | 2 days ago47% | 2 days ago84% |
MACD ODDS (%) | 2 days ago59% | 2 days ago80% |
TrendWeek ODDS (%) | 2 days ago48% | 2 days ago80% |
TrendMonth ODDS (%) | 2 days ago42% | 2 days ago78% |
Advances ODDS (%) | 7 days ago53% | 7 days ago83% |
Declines ODDS (%) | 3 days ago49% | 3 days ago78% |
BollingerBands ODDS (%) | 2 days ago48% | 2 days ago73% |
Aroon ODDS (%) | 2 days ago48% | 2 days ago80% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MLVGX | 19.65 | 0.01 | +0.05% |
MFS Low Volatility Equity C | |||
SROCX | 11.58 | -0.02 | -0.17% |
Calamos Antetokounmpo Sustainable Eqs C | |||
PSSPX | 27.38 | -0.06 | -0.22% |
Principal SmallCap S&P 600 Index R5 | |||
AAAQX | 11.55 | -0.03 | -0.26% |
DWS RREEF Real Assets R | |||
GSAOX | 14.73 | -0.08 | -0.54% |
Goldman Sachs Small Cap Gr Insghts A |
A.I.dvisor tells us that ROAM and BIDU have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ROAM and BIDU's prices will move in lockstep.
Ticker / NAME | Correlation To ROAM | 1D Price Change % | ||
---|---|---|---|---|
ROAM | 100% | +0.06% | ||
BIDU - ROAM | 12% Poorly correlated | -0.84% | ||
YUMC - ROAM | 11% Poorly correlated | -0.05% | ||
RDY - ROAM | 9% Poorly correlated | +0.22% | ||
TCOM - ROAM | 8% Poorly correlated | +1.12% | ||
JD - ROAM | 8% Poorly correlated | -0.56% | ||
More |